| Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum |
2020-06-13 |
| JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV |
2020-06-12 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics |
2020-06-11 |
| Zelluna–SEVERAL: grant, 202006 public grants + equity financing tog totalling €7.5m |
2020-06-11 |
| Zelluna–SEVERAL: investment, 202006 equity financing tog with public grants totalling €7.5m |
2020-06-11 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Evox Therapeutics–Lilly: credit, 202006–202102 convertible bond $10m converted in 2/21 |
2020-06-09 |
| Lilly–Evox Therapeutics: drug delivery technology, 202006– collab + license $20m upfront+ $1.2b milestones DeliverEX for RNAi /ASO for CNS diseases |
2020-06-09 |
| Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications |
2020-06-08 |
| Zeincro–Excelya: investment, 202007 acquisition |
2020-06-07 |
| Shorla Pharma–Ireland (govt): investment, 202006 financing round Series A totalling $8.3m incl co-investor Enterprise Ireland |
2020-06-06 |
| Shorla Pharma–OTHER: investment, 202006 financing round Series A totalling $8.3m incl Irish + Canada-based family offices as co-investors |
2020-06-06 |
| Shorla Pharma–Seroba: investment, 202006 financing round Series A totalling $8.3m incl lead investor Seroba Life Sciences |
2020-06-06 |
| Shorla Pharma–SEVERAL: investment, 202006 financing round Series A $8.3m led by Seroba Life Sciences |
2020-06-06 |
| Tropic Biosciences–SEVERAL: investment, 202006 financing round Series B $28.5m led by Temasek |
2020-06-04 |
| Tropic Biosciences–Temasek: investment, 202006 financing round Series B totalling $28.5m incl new + lead investor Temasek |
2020-06-04 |
| Base Genomics–SEVERAL: investment, 202006 seed financing round £9m ($11m) led by Oxford Sciences Innovation |
2020-06-03 |
| Base Genomics–Univ Oxford: investment, 202006 seed financing round totalling £9m incl lead investor Oxford Sciences Innovation |
2020-06-03 |
| Base Genomics–Zyme Communications: public relations, 202006 service existent by Zyme |
2020-06-03 |
| NodThera–Novo Group: investment, 202006 financing round Series B totalling £44m ($55m) incl lead investor Novo Ventures |
2020-06-03 |
| NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures |
2020-06-03 |
| Prilenia–Instinctif Partners: public relations, 202006 service existent by Instinctif |
2020-06-03 |
| Rigenerand–Image Box: public relations, 202005– supply service by Image Box PR |
2020-05-29 |
| Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility |
2020-05-27 |
| Exscientia–BMS: investment, 202005 financing round Series C totalling $60m incl existing + co-investor BMS |
2020-05-26 |
| Exscientia–Evotec: investment, 202005 financing round Series C totalling $60m incl existing + co-investor Evotec |
2020-05-26 |
| Exscientia–GT Healthcare Capital Partners: investment, 202005 financing round Series C totalling $60m incl existing + co-investor GT Healthcare |
2020-05-26 |
| Exscientia–Novo Group: investment, 202005 financing round Series C totalling $60m incl new + lead investor Novo Holdings |
2020-05-26 |
| Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital |
2020-05-26 |
| Tollys–Andrew Lloyd Associates: public relations, 202005 service existent by ALA |
2020-05-26 |
| GSK–Samsung: biologics contract manufacturing, 202005–2028 supply up to $231m of Benlysta + other biologics by Samsung Biologics |
2020-05-21 |
| Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins |
2020-05-19 |
| Kaiku Health–Elekta: investment, 202005 acquisition 100% of Kaiku Health by Elekta |
2020-05-15 |
| Calliditas Therapeutics–SEVERAL: investment, 202005–202006 private placement SEK82.9m with 924k common shares at SEK89.7/share outside US |
2020-05-14 |
| Calliditas Therapeutics–SEVERAL: investment, 202005–202007 US IPO $81m+$6.9m with w 8.3m+707k common shares as ADSs at Nasdaq Global Market |
2020-05-14 |
| FairJourney Biologics–GHO Capital: investment, 202005 investment by GHO Capital to facilitate acquisition of Iontas by FJB |
2020-05-13 |
| Iontas–FairJourney Biologics: investment, 202005 acquisition of Iontas by FJB facilitaed by investment from GHO Capital |
2020-05-13 |
| Ori Biotech–CellGenix: reagents, 202005– collab supply of GMP raw materials for closed-system CGT manufacturing system of Ori |
2020-05-13 |
| Polyganics–Instinctif Partners: public relations, 202005 service existent by Instinctif |
2020-05-13 |
| Optibrium–OpenEye Scientific: cheminformatics, 202005– collab product integration OE libraries + toolkits with StarDrop software |
2020-05-12 |
| Optimapharm–TRG Management: investment, 202005 investment by The Rohatyn Group to grow organically + via acquisitions |
2020-05-12 |
| Exscientia–SRI International: drug discovery technology, 202005– collab integration SynFini + Centaur Chemist for drug discovery for oncology target |
2020-05-05 |
| Oncopeptides–SEVERAL: investment, 202005 directed share issue SEK1.414b ($144m) with 12.295m new shares at SEK115/share |
2020-05-05 |
| Beckley Psytech–PERSON: investment, 202005 financing round Series A totalling £3m incl investor Jim Mellon |
2020-05-01 |
| Beckley Psytech–PERSON: investment, 202005 financing round Series A totalling £3m incl investor Richard Reed |
2020-05-01 |
| Beckley Psytech–SEVERAL: investment, 202005 financing round Series A £3m |
2020-05-01 |
| Hyloris Pharmaceuticals–Consilium: public relations, 202004 service existent by CSC |
2020-04-30 |
| Lifebit–Beacon Capital: investment, 202004 financing round Series A totalling £6m incl existing + co-investor Beacon Capital |
2020-04-30 |
| Lifebit–Connect Ventures: investment, 202004 financing round Series A totalling £6m incl existing + co-investor Connect Ventures |
2020-04-30 |
| Lifebit–Eurazeo: investment, 202004 financing round Series A totalling £6m incl new + lead investor Idinvest Partners |
2020-04-30 |
| Lifebit–Pentech Ventures: investment, 202004 financing round Series A totalling £6m incl existing + co-investor Pentech Ventures LLP |
2020-04-30 |
| Lifebit–SEVERAL: investment, 202004 financing round Series A £6m led by new investor Idinvest Partners |
2020-04-30 |
| Compass Pathways–Able Partners: investment, 202004 financing round Series B totalling $80m incl new investor Able Partners |
2020-04-27 |
| Compass Pathways–Atai Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor Atai Life Sciences |
2020-04-27 |
| Compass Pathways–Camden Partners: investment, 202004 financing round Series B totalling $80m incl new investor Camden Partners Nexus |
2020-04-27 |
| Compass Pathways–Founders Fund: investment, 202004 financing round Series B totalling $80m incl new investor Founders Fund |
2020-04-27 |
| Compass Pathways–Otsuka: investment, 202004 financing round Series B totalling $80m incl new investor MSRD |
2020-04-27 |
| Compass Pathways–Perceptive Advisors: investment, 202004 financing round Series B totalling $80m incl new investor Perceptive Advisors |
2020-04-27 |
| Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors |
2020-04-27 |
| Compass Pathways–Skyviews Life Science: investment, 202004 financing round Series B totalling $80m incl new investor Skyviews Life Science |
2020-04-27 |
| Compass Pathways–Soleus Capital: investment, 202004 financing round Series B totalling $80m incl new investor Soleus Capital |
2020-04-27 |
| SwanBio Therapeutics–Syncona: investment, 202004 expanded financing round Series A totalling $52m incl investor Syncona Ltd |
2020-04-23 |
| EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners |
2020-04-22 |
| EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund |
2020-04-22 |
| FoRx Therapeutics–Optimum Strategic Communications: public relations, 202004 service existent by Optimum |
2020-04-22 |
| Nanna Therapeutics–Astellas: investment, 202004 acquisition 100% for £12m upfront + £57.5m milestones by Astellas Pharma Europe Ltd |
2020-04-21 |
| MicrofluidX–88 Capital: investment, 202004 seed financing round totalling £1.4m incl angel contributions from 88 Capital |
2020-04-20 |
| MicrofluidX–Cambridge Angels: investment, 202004 seed financing round totalling £1.4m incl angel contributions from Cambridge Angels |
2020-04-20 |
| MicrofluidX–Longwall Ventures: investment, 202004 seed financing round totalling £1.4m incl investor Longwall Ventures |
2020-04-20 |
| MicrofluidX–Midven: investment, 202004 seed financing round totalling £1.4m incl investor UKI2S |
2020-04-20 |
| MicrofluidX–Moulton Goodies: investment, 202004 seed financing round totalling £1.4m incl investor Moulton Goodies Ltd |
2020-04-20 |
| MicrofluidX–SEVERAL: investment, 202004 seed financing round £1.4m from UKI2S + Longwall Ventures + Moulton Goodies + angel investors |
2020-04-20 |
| Avectas–PERSON: investment, 202004 financing round Series C totalling $20m incl existing + co-lead investor Seamus Mulligan |
2020-04-16 |
| Avectas–SEVERAL: investment, 202004 financing round Series C $20m led by exisiting shareholders incl Seamus Mulligan |
2020-04-16 |
| Evox Therapeutics–Cevec: cell line technology, 202004– license €na for use of CAP technology to produce exosome therapeutics as part of ongoing collab |
2020-04-16 |
| Leo Pharma–Oneness Biotech: therapeutic antibody, 202004– license ww excl to FB825 $40m upfront + $530m milestones + royalties from Oneness + MBS |
2020-04-15 |
| PIC Therapeutics–Advent Life Sciences: investment, 202004 seed financing round totalling $5m inc lead investor Advent Life Sciences |
2020-04-15 |
| Amphista Therapeutics–Advent Life Sciences: investment, 202004 financing round Series A totalling $7.5m incl lead investor Advent Life Sciences |
2020-04-07 |
| Amphista Therapeutics–BioMotiv: investment, 202004 financing round Series A totalling $7.5m incl new + co-investor BioMotiv |
2020-04-07 |
| Amphista Therapeutics–EU (govt): investment, 202004 financing round Series A totalling $7.5m incl existing seed + co-investor European Investment Fund |
2020-04-07 |
| Amphista Therapeutics–Scius Communications: public relations, 202004 supply service existent by Scius Communications |
2020-04-07 |
| Amphista Therapeutics–Scotland (govt): investment, 202004 financing round Series A totalling $7.5m incl existing seed + co-investor SIB |
2020-04-07 |
| Amphista Therapeutics–SEVERAL: investment, 202004 financing round Series A $7.5m led by Advent Life Sciences + incl SIB + EIF + BioMotiv |
2020-04-07 |
| Gadeta–Optimum Strategic Communications: public relations, 202004 service existent by Optimum |
2020-04-07 |
| GSK–Vir Biotechnology: virostatic agents, 202004– collab RnD antiviral MAbs incl VIR-7831 + VIR-7832 targeting SARS-CoV-2 |
2020-04-06 |
| Vir Biotechnology–GSK: investment, 202004 equity investment $250m at $37.73/share (10% premium to share price 27 Mar 2020) in connection with collab |
2020-04-06 |
| Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Plesner: legal services, 202004 supply service Plesner AP legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Rothschild & Co: financial services, 202004 supply service Rothschild & Co financial advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Servier: investment, 202004–202006 acquisition 100% €na |
2020-04-03 |
| Axxam–ERS Genomics: CRISPR technology, 202004– license ww €na for drug discovery services of Axxam |
2020-04-02 |
| iTeos Therapeutics–Janus Henderson: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor Janus Henderson Investors |
2020-04-01 |
| Vaderis Therapeutics–Almac: allosteric AKT inhibitors, 202004 acquisition portfolio of allosteric AKT inhibitors from Almac Discovery Ltd by Vedaris |
2020-04-01 |
| Gilde Investment–Denmark (govt): investment, 202003 first + final close of Gilde Healthcare V fund totalling €416m incl investor Vaekstfonden |
2020-03-31 |
| Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche |
2020-03-31 |
| Evox Therapeutics–FTI Consulting: public relations, 202003 service existent by FTI Consulting |
2020-03-26 |
| SutroVax–Abingworth: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Abingworth |
2020-03-26 |
| SutroVax–Medicxi: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Medicxi |
2020-03-26 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 ... 17 18 19 ... 32 33 34 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
